Difference between revisions of "Epratuzumab (LymphoCide)"
Jump to navigation
Jump to search
m (Jwarner moved page Epratuzumab (humanised anti-CD22 antibody) to Epratuzumab (LymphoCide): brand name available) |
m |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Acute lymphocytic leukemia]]=== | ===[[Acute lymphocytic leukemia]]=== | ||
| − | # Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https://www.ncbi.nlm.nih.gov/pubmed/24579885 PubMed] [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] | + | # '''SWOG S0910:''' Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. [https://www.ncbi.nlm.nih.gov/pubmed/24579885 PubMed] [https://onlinelibrary.wiley.com/doi/10.1111/bjh.12778/full link to original article] |
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' AMG 412 | ||
| + | *'''Brand name:''' LymphoCide | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 17:47, 5 August 2019
Mechanism of action
Anti-CD22 antibody
Preliminary data
Acute lymphocytic leukemia
- SWOG S0910: Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article
Also known as
- Code name: AMG 412
- Brand name: LymphoCide